With advancing age, an increased visibility of perivascular spaces (PVSs) on magnetic resonance imaging (MRI) is hypothesized to represent impaired drainage of interstitial fluid from the brain and may reflect underlying cerebral small vessel disease (SVD). However, whether large perivascular spaces (L-PVSs) (>3 mm in diameter) visible on MRI are associated with SVD and cognitive deterioration in older individuals is unknown.
C erebral small vessel disease (SVD) is a major contributor to cognitive impairment in older individuals. 1, 2 In addition to well-established neuroimaging hallmarks of SVD, including small subcortical infarcts, white matter hyperintensities (WMHs), and microbleeds, magnetic resonance imaging (MRI)-visible perivascular spaces (PVSs) are emerging as a potential SVD marker. The PVSs are fluid-filled cavities that surround small, penetrating cerebral arterioles and venules and are commonly considered to play an important role in forming a network of drainage channels for the elimination of metabolic waste and fluid from the brain. 3 When the caliber and the number of normally microscopic PVSs increases with advancing age, PVSs appear on T2-weighted MRI as round or tubular hyperintensities in the basal ganglia and white matter. [4] [5] [6] With regard to pathologic features, the mechanisms underlying the PVSs may involve the 2 most common sporadic forms of SVD, which are hypertensive arteriopathy and cerebral amyloid angiopathy (CAA), plausibly leading to different anatomical PVS patterns. 1, 7 There is increasing epidemiologic evidence that PVSs are associated with some MRI manifestations of SVD and cognitive impairment in patients with cerebrovascular disease [8] [9] [10] or dementia 11, 12 and in neurologically healthy adults. 7, 13, 14 To date, longitudinal data are scarce, 15 and the clinical significance of PVSs in the general population of older individuals remains uncertain. Looking prospectively at the association would help to disentangle the complex interplay between PVSs and other SVDs and better define the cognitive consequence of PVSs. Previous studies [7] [8] [9] [10] 16 focused on detecting smaller PVS lesions with a maximum diameter less than 3 mm on MRI in an attempt to separate PVSs from lacunes of presumed vascular origin, although pathologic studies 17, 18 have not found an absolute cutoff size to discriminate between the 2 lesions. We examined large PVSs (L-PVSs) with diameters greater than 3 mm, which are morphologically distinguished from lacunes on MRI. Large PVSs are frequently encountered in ostensibly healthy older individuals, and their prevalence increases with higher numbers of smaller PVSs. 19 We thus investigated in a large, well-characterized cohort of older individuals the prospective associations between prevalent L-PVSs and progression of the MRI markers of SVD, cognitive decline, and risk of new-onset dementia.
Methods

Participants
This investigation was conducted as part of the prospective, population-based Age, Gene/Environment SusceptibilityReykjavik (AGES-Reykjavik) Study, which originates from the Reykjavik Study, as described in detail previously. 20 In brief, 2) years apart. Of the 3316 participants who attended the follow-up examination, we excluded 654 participants if the baseline MRIs were unavailable, incomplete, or of inadequate quality. In total, 2612 participants without prevalent dementia were included in the SVD progression analysis. Of these, 2592 participants were included in the dementia analysis and 2551 participants were included in the cognitive decline analysis (eMethods, eFigure 1, and eTable 1 in the Supplement). All participants gave written informed consent, and all data were deidentified. The study was approved by the Icelandic National Bioethics Committee and the National Institute on Aging Intramural Institutional Review Board.
Brain MRI and L-PVS Assessment
We performed brain MRI on a study-dedicated 1.5-T scanner (Signa Twinspeed; General Electric Medical Systems). The same MRI protocol, described elsewhere, [21] [22] [23] was used at baseline and follow-up and included the following pulse sequences 21 : 3-dimensional, T1-weighted, spoiled-gradient echo sequence; proton density/T2-weighted fast spin echo sequence; fluid attenuated inversion recovery (FLAIR) sequence, and T2*-weighted gradient-echo-type echo planar (eMethods in the Supplement). The volume of WMH was quantified automatically and expressed as the percentage of total intracranial volume. 22 Microbleeds were defined as a focal area of signal void in the brain parenchyma that was visible on T2*-weighted gradient-echotype echo planar and smaller or invisible on T2-weighted fast spin-echo scans. 21,23,24 Subcortical infarcts were defined as brain parenchymal defects with a minimum diameter of 4 mm not extending into the cortex, with a signal intensity equal to cerebrospinal fluid on all pulse sequences and surrounded by an area of high signal intensity on FLAIR images.
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To distinguish PVSs from subcortical infarcts, L-PVSs were evaluated separately and defined as round or tubular defects with a short axis larger than 3 mm in the subcortical area, without a rim or area of high signal intensity on the axial FLAIR
Key Points
Question What is the effect of large perivascular spaces (diameters >3 mm) visible on magnetic resonance imaging on progression of magnetic resonance imaging hallmarks of cerebral small vessel disease, cognitive decline, and dementia in a general population?
Findings In this prospective, population-based cohort study of 2612 older adults, the prevalence of large perivascular spaces was 16.2%. Large perivascular spaces were associated with progression of subcortical infarcts, microbleeds, and white matter hyperintensities and decline in information processing speed and more than quadrupled the risk of vascular dementia during a 5-year follow-up.
Meaning Large perivascular spaces are prevalent in the older population; as markers of small vessel disease, they should be included in assessments of vascular cognitive decline.
(characteristics for infarcts) and without evidence of hemosiderin in its wall on the axial T2*-weighted gradient-echotype echo planar (characteristics for resorbed hemorrhagic lesions) (Figure) . The total L-PVS number was based on the presence in the basal ganglia complex (caudate nucleus, internal capsule, external capsule, thalamus, and lentiform nucleus [putamen and globus pallidus]) along the paths of the perforating lenticulostriate arteries (arising from the middle cerebral artery) and in white matter along the paths of the perforating medullary arteries. Intrarater reliability values (κ) for L-PVSs based on 2 ratings within a 6-month interval were 0.88 and 0.93, and the interrater agreement value was 0.66, indicating good reliability. Our scan protocol could not be designed to capture smaller PVSs (ie, ≤3 mm in diameter) because the section thickness of the 2-dimensional FLAIR, proton density, and T2-weighted scans was 3 mm, and the nature of smaller lesions was more difficult to assess reliably.
The presence of L-PVSs, microbleeds, and subcortical infarcts on the baseline and follow-up scans was assessed by trained radiographers. They were initially masked to the baseline MRI and identified new lesions on the follow-up MRI. If a lesion was detected on the follow-up MRI, the baseline MRI was examined to determine whether the lesion was present in the same section location. If so, the follow-up lesion was labeled prevalent; if not, the lesion was labeled incident.
Assessment of Cognitive Function
Participants underwent a neuropsychological test battery that assessed 3 cognitive domains 25 : verbal memory, processing speed, and executive function (eMethods in the Supplement). The composite score for each cognitive domain was calculated by converting raw scores to standardized z scores and averaging them across all tests for the domain. 25 For each participant, we computed z scores for baseline and follow-up using the mean (SD) of the baseline test scores. Cognitive decline was calculated by subtracting the baseline domain-specific z scores from the follow-up z scores.
Dementia Diagnosis
Incident dementia cases were identified at follow-up examination based on a 3-step procedure, and the diagnosis of dementia and subtypes was assigned at a consensus conference (eMethods in the Supplement). 25 Vascular dementia (VaD) was diagnosed in accordance with the criteria of the State of California Alzheimer Disease Diagnostic and Treatment Centers.
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Statistical Analysis
Large PVSs were further categorized into a trichotomous variable (none, 1, and ≥2). Because the anatomical distribution of L-PVSs may reflect different SVD types, we also examined L-PVSs by location: a white matter distribution exclusively and those in the basal ganglia with and without concomitant white matter L-PVSs. We constructed multiple logistic regression models and performed the postestimations (Stata adjrr command) to calculate the adjusted risk ratios (aRRs; ie, the ratio of the mean predicted probabilities between those with and without the L-PVSs) and 95% CIs for the associations between L-PVS presence and incident subcortical infarcts, microbleeds, and dementia. We estimated the association between L-PVS presence and subsequent WMH progression and cognitive decline by multiple linear regression analyses. The change scores for WMH volume and processing speed were logarithmically transformed to normalize their skewed distributions. All analyses were initially adjusted for age, sex, and interval between the baseline and follow-up MRIs (model 1), followed by additional adjustment for head coil, body mass index, current smoking, hypertension, total cholesterol level, prevalent symptomatic stroke, and APOE4 genotype (model 2). With respect to the association with cognitive outcomes, we adjusted for educational level, depression, baseline cerebral infarcts, microbleeds, and WMHs in addition to the aforementioned variables (except for stroke) in model 2. Interactions between L-PVSs and other covariates with respect to effects on SVD and cognitive outcomes were assessed in the fully adjusted models by including cross-product terms of each covariate with L-PVSs. All analyses were repeated for the number and location of L-PVSs, and the association with L-PVS location was examined while controlling for L-PVSs at other locations. Because the occurrence of dementia events was low (n <5) in L-PVS number or location categories, we applied the Fisher exact test to examine the crude associations between L-PVS number or location and dementia. To test the robustness of the results, we performed several sensitivity analyses (eMethods, eResults, and eTables 2 and 3 in the Supplement). We used 2-tailed t tests and Wald tests as appropriate, and a 2-sided P ≤ .05 was taken to indicate statistical significance.
Results
Of the 2612 study patients ( mixed L-PVSs in both locations, n = 42). The cumulative incidence of SVD and dementia is listed in the eResults in the Supplement.
L-PVSs and Incident SVD
The presence of L-PVSs at baseline was associated with an increased risk of incident subcortical infarcts and microbleeds and greater WMH progression (model 1) ( Table 2 ). For each SVD marker, the number of L-PVSs increased: both 1 and 2 or more L-PVSs were associated with increased risk of incident subcortical infarcts and microbleeds and promoted a greater WMH progression, with the associations being strongest for 2 or more L-PVSs. When stratified according to L-PVS location, associations with subcortical infarcts and WMHs were found for basal ganglial L-PVSs, whereas an association with incident microbleeds was found for white matter and basal ganglia L-PVSs. When further adjusted for major cardiovascular risk factors, stroke, and APOE4 genotype (model 2), all associations persisted except for the association between 1 L-PVS and WMH progression. There were no interactions of L-PVSs with any of the covariates.
L-PVSs, Cognitive Decline, and Dementia
The presence of L-PVSs was associated with a steeper decline in information processing speed (model 1) ( Table 3) . Participants with 2 or more L-PVSs had the greatest decline in processing speed compared with those with no L-PVSs, with an intermediate decline for participants with 1 L-PVS. Furthermore, an association with processing speed was found for basal ganglia L-PVSs. In the fully adjusted models, these estimates were attenuated for the presence of increasing L-PVS number. No association of L-PVSs was found for memory or executive function.
In the fully adjusted model, the presence of L-PVSs was associated with an increased risk of developing VaD (model 1: aRR, 4.19; 95% CI, 1.81-9.69; P < .001; model 2: aRR, 3.34; 95% CI, 1.41-7.93; P = .006) but not with all-cause dementia (model 1: aRR, 1.47; 95% CI, 1.00-2.18; P = .06; model 2: aRR, 1.32; 95% CI, 0.89-1.97; P = .18) or Alzheimer disease (model 1: aRR, 1.23; 95% CI, 0.75-2.03; P = .44; model 2: aRR, 1.16; 95% CI, 0.66-2.05; P = .62). The presence of a single L-PVS or basal ganglia L-PVS was associated with a higher incidence of VaD (eFigure 2 and eFigure 3 in the Supplement).
Discussion
In the general population of older individuals free of prevalent dementia at baseline, we found that the presence of L-PVSs was associated with new subcortical infarcts, microbleeds, and WMH progression during a 5-year period. Furthermore, compared with individuals with no L-PVSs, those with baseline L-PVSs had a greater decline in processing speed and an increased likelihood of developing VaD. To our knowledge, this is the first longitudinal demonstration to date that L-PVSs are a risk factor for SVD progression and VaD. Previous studies, mostly of cross-sectional design, found an association between smaller PVSs and MRI markers of SVD, 7-10 worse cognitive performance, 13,28 and dementia. 15 Although a diameter of 3 mm was generally used as a cutoff to differentiate smaller PVSs from lacunes, the size criteria to discriminate the lesions on MRI has been the subject of debate and is not confirmed pathologically. 16, 17 The empirical evidence from a large, population-based MRI study 19 indicates that although smaller PVSs are always detected in basal ganglia or white matter in older individuals, L-PVSs are also prevalent. Of importance, the prevalence of L-PVSs significantly increases with the severity of smaller PVSs. 19 Our results indicate the associations with those large lesions and add new insights into the potential clinical significance of L-PVSs in a community-based cohort of older adults. Our results thus lend strong support to the hypothesis that L-PVSs, likely representing a more severe form of the lesion spectrum, serve as another key MRI manifestation of SVD and may reflect processes related to the pathogenesis of VaD. Perivascular spaces follow the course of the penetrating arterioles and are important drainage conduits for cerebral interstitial fluid, solutes, and metabolic waste into the ventricles and for inflammatory and immunologic processes. 29 Some studies 30, 31 suggest that PVSs may be an epiphenomenon and a precursor of SVD. For example, WMHs tend to form around PVSs, and thus PVSs have been speculated to be an imaging biomarker for early alteration of arteriolar wall and blood-brain barrier function that may eventually lead to hemosiderin leakage and lesions in the perivascular parenchyma. 29 Although the association between L-PVSs and SVD progression provides support for such a notion, we also found that the presence of SVD markers at baseline was significantly associated with incident L-PVSs, suggesting the challenges in determining temporality among these lesions. This observed bidirectional association in our study implies the complex interplay between L-PVSs and SVD markers and further strengthens the notion that shared microvascular pathways are involved to mediate the interplay. One potential mechanism is that the structural changes in the microvascular wall could gradually impair the external drainage of the interstitial fluid and solutes along the basement membranes, causing retrograde dilation of PVSs by diminishing the pulsatility of small vessels owing to smooth muscle cell loss or by blocking bulk flow. 30,32,33 Impaired perivascular drainage could then further exacerbate solute deposition, including damaged peptides (eg, leptomeningeal and superficial cortical vascular amyloid-β), creating a feed-forward loop.
34,35
We found that SVD associations with L-PVSs may differ by their distribution, possibly suggesting different pathophysiologic mechanisms relevant to the presumed underlying arteriopathy. The association with incident subcortical infarcts and WMH progression is significant for basal ganglia L-PVSs, Abbreviations: L-PVSs, large perivascular spaces; MRI, magnetic resonance imaging.
a Cognitive change was defined as the difference between composite cognitive z score at follow-up and at baseline; a negative-change score indicates cognitive decline.
b Change scores for processing speed were natural log transformed. which are driven mainly by hypertensive arteriopathy that affects deep perforators. [7] [8] [9] [10] The association with incident microbleeds remains significant for L-PVSs in both locations. The spatial distribution of microbleeds reflects specific microvascular pathologic findings (ie, hypertensive arteriopathy and CAA), and the presence of cortical microbleeds or multiple strictly lobar microbleeds is a putative neuroimaging marker of CAA. 34, 36 The CAA that affects the parent leptomeningeal or cortical arteries that supply the subcortical white matter may underlie the link between white matter L-PVSs and microbleeds. 37,38 However, the lack of an association of white matter L-PVSs with incident subcortical infarcts or WMH progression could be potentially attributable to low statistical power.
The associations of L-PVSs with a greater decline in processing speed and higher risk of VaD were independent of MRI markers of cerebrovascular disease, suggesting that they were not simply attributable to confounding by other vascular mechanisms. Furthermore, the associations remain significant for L-PVSs in basal ganglia. Our findings are consistent with the hypothesis that SVD contributes to a profile of vascularrelated cognitive impairment 2, 39 and suggest that L-PVS may be part of the pathologic spectrum that links hypertension and arteriosclerosis to VaD. Alternatively, the observed associations could be secondary to inflammatory cell accumulation and microglial activation, 3 ,40,41 which may be another common pathophysiologic mechanism shared by L-PVSs and cognitive deterioration. However, additionally controlling for circulating C-reactive protein or white blood cell count did not alter these associations.
Strengths and Limitations
Major strengths of the present study include the large population-based sample of older individuals free of dementia at baseline and followed up for a mean of 5 years, the use of standard MRI and reliable assessment of MRI lesions, and the extensive characterization of participants that enabled us to adjust for a series of potential confounders. Our study has several limitations. First, cohort members included in the analysis were younger, more educated, and healthier at baseline than those with missing data (eTable 1 in the Supplement). Individuals with worse vascular risk profile or more severe SVD (those more likely to develop cognitive decline and dementia) died or were lost to follow-up before they could be recruited into the follow-up examination. This attrition may affect our estimates. 
Conclusions
Large PVSs mark the progression of SVD and are associated with cognitive decline and VaD in older individuals. From a clinical perspective, our findings strengthen the notion that L-PVSs serve as an MRI marker of SVD and suggest that L-PVSs (and the pathomechanisms leading to their dilatation) could be a potential target for therapies and prevention strategies of SVDs and vascular-related cognitive impairment.
manuscript; and the decision to submit the manuscript for publication. 1 These latter three sequences were acquired with 3-mm thick interleaved slices. Total brain parenchymal volume (an index of brain atrophy) was quantified automatically and expressed as the percentage of total intracranial volume.
2 A parenchymal defect was described morphologically as a defect of the brain parenchyma with a signal intensity equal to that of cerebrospinal fluid on all pulse sequences. 3 Cortical infarcts were defined as defects involving or limited to the cortical ribbon and surrounded by an area of high signal intensity on FLAIR images. 3 No size criteria was considered for defects in the cerebellum. Total cerebral infarcts consisted of subcortical, cortical, and cerebellar infarcts. From October 7, 2003 and onwards, the four-channel phased array head cap coil was upgraded to the eight-channel during the study. One third participants at baseline had the four-channel head coil. A study of repeated scans with 2 head coils showed little impact on brain volumetric measurements. 
Assessment of cognitive function
Diagnosis of dementia and subtypes
All participants were screened using the Mini-Mental State Examination and the DSST. 3 People who were positive at screening completed an additional diagnostic test battery including the Trails A and B and the Rey Auditory Verbal Learning tests. 3 Those who were then suspected to have dementia went for a final assessment that included a proxy interview and neurologic examination. 3 Dementia was diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). 4 The diagnosis of Alzheimer's disease was in accordance with the criteria for possible, probable or definite Alzheimer's disease published by the National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association. 5 The diagnosis of vascular dementia was based on criteria for possible or probable vascular dementia (VaD) published by the State of California Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC). 6, 7 Specifically, for probable VaD, ADDTC criteria require all the following 1. Dementia; 2. Evidence of two or more ischemic strokes or a single stroke with a clear temporal relationship to the onset of dementia; 3. Evidence of at least one infarct outside the cerebellum. 6 For possible VaD, ADDTC criteria include dementia diagnosis and one or more of the following: 2a. History or evidence of a single stroke without a clear temporal relationship to dementia onset or 2b. Binswanger's disease that includes all of the following: (i) early onset of urinary incontinence or gait disturbance; (ii) vascular risk factors; (iii) extensive white matter changes seen on neuroimaging.
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Other baseline measures Education level (primary vs. secondary/college/university education) and cigarette smoking history (current vs. former/never) were assessed by questionnaire. Depressive symptoms were assessed by the 15-item Geriatric Depression Scale (GDS-15; score range, 0 to 15) and participants with scores ≥ 6 were classified as having high depressive symptomatology. Current use of medications (e.g., use of drugs lowering blood pressure, use of drugs lowering blood glucose, statin use) was assessed from vials presented at the clinic. Body mass index was calculated as weight (kg) divided by height squared (m 2 ). Fasting total cholesterol was determined on a Hitachi 912 instrument using comparable enzymatic procedures (Roche Diagnostics, Mannheim, Germany).
8 Systolic (SBP) and diastolic (DBP) blood pressures were measured in recumbent position with a standard mercury sphygmomanometer, and the mean of two consecutive blood pressure measurements was used. Hypertension was defined as SBP ≥140 mmHg, DBP≥90 mm Hg or by the use of antihypertensive medications. Type 2 diabetes was ascertained through self-reported history of diabetes, use of diabetic medication or insulin, or a fasting blood glucose level≥7.0 mmol/l. Prevalent symptomatic stroke was ascertained from hospital medical records or the registry of adjudicated cases on stroke. Apolipoprotein E (APOE) genotyping was carried out using standard DNA amplification and restriction isotyping. People with 2 4, 3 4 and 4 4 genotype were grouped together as 4 carriers ( 4+), and people with genotypes 2 2, 2 3 and 3 3 were grouped together as noncarriers ( 4-).
8
Analytic cohort
Reasons for not attending the follow-up examination included: death (n=1,039); refusal (n=1,198); and loss to follow-up (not deceased but could not be contacted through any means) (n=211). Of the 3,316 participants who attended the follow-up examination, 654 had missing MRI at baseline due to contraindications (n=272), refusal / nonattendance (n=337), or technical reasons (i.e. no qualitatively acceptable data available for all necessary sequences; n=45). This resulted in 2662 people with complete and reliable baseline and follow-up MRI data (eFigure.1). We further excluded 50 participants who had a diagnosis of prevalent dementia (n=37) or missing cognitive status (n=13) at baseline, which resulted 2612 participants for analyses of SVD progression. Among them, 2,592 participants were included for analyses of cognitive outcomes (eFigure.1). For incident dementia, we further excluded 1 participant with dementia diagnosis missing at follow-up, which resulted in 2,591 participants. For cognitive decline, we further excluded 41 participants without follow-up cognitive composite scores, which resulted in 2,551 participants. Participants excluded for the present analysis, as compared with those who met inclusion criteria, were more likely to be older and APOE 4 allele carriers, less educated, and to have a higher prevalence of depressive symptoms, and worse cardiovascular profile of risk factors and disease (all p values <0.05) (eTable 1).
Statistical analysis
We graphically assessed the linearity of age and other continuous covariates in the models. For example, odds ratios were calculated for each quarter of age distributions and plotted on the log scale against mean age within each quartile in the logistic regression models (Stata LINCHECK). Standardized residuals or augmented componentplus-residuals (Stata acprplot) against age were plotted to detect non-linearity in a linear regression model. Because these plots did not indicate strongly a clear departure from linearity for age, we modelled age as a continuous variable in all models. To test the robustness of the results, we did several sensitivity analyses. We examined the white matter L-PVS group when including participants with concomitant basal ganglia L-PVS and reran analyses for the 'extended' white matter L-PVS group. The association of L-PVS with each marker of SVD progression was additionally mutually adjusted for other SVD markers at baseline. For example, the association with incident microbleeds was further controlled for baseline subcortical infarcts and WMH. To further examine the potential confounding effect of blood pressure, we adjusted for systolic and diastolic blood pressure levels simultaneously in the models instead of 'hypertension'. We also carried out further adjustment for brain atrophy or hippocampal atrophy (calculated as the residual from a linear regression of hippocampal volume vs. the total intracranial volume) in the models and reran analyses. Given participants with basal ganglia L-PVS tended to have a higher L-PVS count (i.e. ≥ 2) than those with white matter L-PVS exclusively (29% vs. 12%), we explored the effect of systematic inter-location difference in L-PVS numbers on location-specific associations by additionally adjusting for L-PVS count. We repeated analyses after excluding those with either prevalent (baseline) or incident cortical infarcts to examine the associations of L-PVS with progression of WMH. Finally, to assess the extent to which other SVD markers lead to the development of new L-PVS, analyses were repeated with baseline presence of SVD markers as the exposure variable and incident L-PVS over time as the outcome.
Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) and Stata version 12 (StataCorp LP, College Station, TX, USA), and associations were considered significant at the 0.05 level. 
